Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Katrina Von Kriegenbergh

Pain Medicine Torrance, CA Medical Doctor

NPI 1013270867 CMS profile 137371

3655 Lomita Blvd Ste 206, Torrance, CA 90505

Open in the dashboard

General payments

$22,509

434 records reported · program years 2019–2025

Research payments

$115

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,025 paid to institutions, not to them · program year 2021

Through program year 2025, Katrina Von Kriegenbergh of Torrance, CA is reported in the CMS Open Payments database as having received $22,509 across 434 general payments and $115 in research payments paid to them. Separately, studies naming them as principal investigator received $1,025 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,761 27
2024 General $1,602 47
2023 General $3,248 97
2022 General $7,817 65
2021 General $4,925 112
2021 Research $16 1
2020 General $937 42
2019 General $1,219 44
2019 Research $99 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katrina Von Kriegenbergh
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Katrina Von Kriegenbergh were reported at $2,761. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Katrina Von Kriegenbergh Pain Medicine median Middle half National median
2019 $1,219 $498 $126–$1,682 $163
2020 $937 $284 $80–$910 $114
2021 $4,925 $399 $112–$1,219 $132
2022 $7,817 $455 $137–$1,484 $149
2023 $3,248 $484 $128–$1,495 $160
2024 $1,602 $498 $131–$1,540 $164
2025 $2,761 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $12,306 112 payments
  2. BIOTRONIK NRO, Inc. $1,791 15 payments
  3. Spinal Simplicity, LLC $1,505 20 payments
  4. AbbVie, Inc. $1,299 69 payments
  5. Boston Scientific Corporation $939 20 payments
  6. Medtronic USA, Inc. $813 24 payments
  7. Allergan Inc. $603 54 payments
  8. Abbott Laboratories $452 5 payments
  9. Biohaven Pharmaceuticals, Inc. $310 15 payments
  10. Amgen Inc. $281 7 payments
  11. Other $2,212 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,110 411 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,673 3 payments
  3. Travel and Lodging $3,726 20 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $8,002 64 payments
  2. RESTORE $1,650 1 payment
  3. Prospera $1,511 9 payments
  4. HA MINUTEMAN G3-R $1,505 20 payments
  5. INTELLIS $1,295 25 payments
  6. BOTOX Botox Therapeutic $577 29 payments
  7. BOTOX Hyperhydrosis $547 50 payments
  8. NURTEC ODT $512 26 payments
  9. Vanta $491 9 payments
  10. ADAPTIVESTIM $476 8 payments
  11. Other $6,830 243 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $115 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,013

Median for Anesthesiology: 322

Drug cost

$39,891

Median for Anesthesiology: $8,738

Branded share of claims

31.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 27 $12,898
Movantik Naloxegol Oxalate Brand 19 $7,476
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 195 $5,825
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 59 $2,082
Gabapentin Generic 108 $1,591
Oxycodone Hcl Generic 54 $1,238
Morphine Sulfate Generic 34 $1,026
Tizanidine Hcl Generic 63 $903
Duloxetine Hcl Generic 29 $839
Morphine Sulfate Er Morphine Sulfate Brand 15 $777

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$141,740

Of which drugs: $18,110

Medicare patients

227

Average age 70

Services billed

6,010

138 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 42%
Depression 40%
Chronic kidney disease 30%
Ischemic heart disease 26%
Osteoporosis 24%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 18 3,035 $15,049
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 78 1,423 $129

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $232
$232 — 3,035
UBRELVY
  • AbbVie, Inc. $37
$37 — —
NURTEC ODT
  • PFIZER INC. $26
$26 — —
ZAVZPRET
  • PFIZER INC. $26
$26 — —
PROLATE
  • Forte Bio-Pharma LLC $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

436 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record